Secondary Analyses of the Effects of Lutein/Zeaxanthin on Age-Related Macular Degeneration Progression AREDS2 Report No.3
The Age-Related Eye Disease Study (AREDS) formulation for treatment of age-related macular degeneration contains vitamins C, E, beta-carotene and zinc with copper. Age-Related Eye Disease Study 2 (AREDS2) assessed the value of substituting lutein/zeaxanthin in the AREDS formulation because of the de...
Gespeichert in:
| Veröffentlicht in: | JAMA ophthalmology 2014-02, Vol.132 (2), p.142-149 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 149 |
|---|---|
| container_issue | 2 |
| container_start_page | 142 |
| container_title | JAMA ophthalmology |
| container_volume | 132 |
| creator | Chew, Emily Y. Clemons, Traci E. SanGiovanni, John Paul Danis, Ronald P Ferris, Frederick L. Elman, Michael J. Antoszyk, Andrew Ruby, Alan Orth, David Bressler, Susan B. Fish, Gary Hubbard, Baker Klein, Michael Chandra, Suresh Blodi, Barbara Domalpally, Amitha Friberg, Thomas Wong, Wai Rosenfeld, Philip Agron, Elvira Toth, Cynthia Bernstein, Paul Sperduto, Robert |
| description | The Age-Related Eye Disease Study (AREDS) formulation for treatment of age-related macular degeneration contains vitamins C, E, beta-carotene and zinc with copper. Age-Related Eye Disease Study 2 (AREDS2) assessed the value of substituting lutein/zeaxanthin in the AREDS formulation because of the demonstrated risk of lung cancer from beta-carotene in smokers and former smokers. As previously reported in a secondary analysis, AREDS2 participants taking lutein/zeaxanthin with or without omega-3 long-chain polyunsaturated fatty 3 acids had a slightly lower progression rate to late AMD than participants not taking lutein/zeaxanthin. |
| doi_str_mv | 10.1001/jamaophthalmol.2013.7376 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmedcentral</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4636082</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_4636082</sourcerecordid><originalsourceid>FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_46360823</originalsourceid><addsrcrecordid>eNqlTsFKxDAUDKK4i-4_5AfaTZpu2pNQ3IoHFel68lKe7WubJU1Kkor791YRwbNzmRlmGIYQylnMGePbI4xgpyEMoEer44RxEWcik2dknXCZR5Jn4vxXy92KbLw_sgU5Y6nYXZJVkgrORCrW5HTAxpoW3IkWBvTJo6e2o2FAWnYdNuHbPswBldm-InyACYMy1Bpa9BhVqCFgSx-hmTU4usceDToIaik8O9s79P5LF1W5PyS0wsm6QJ9sLK7JRQfa4-aHr8jNXflyex9N89uIbYMmOND15NS4vKstqPpvYtRQ9_a9TqWQLE_Evwc-AV4GcMo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Secondary Analyses of the Effects of Lutein/Zeaxanthin on Age-Related Macular Degeneration Progression AREDS2 Report No.3</title><source>American Medical Association Journals</source><creator>Chew, Emily Y. ; Clemons, Traci E. ; SanGiovanni, John Paul ; Danis, Ronald P ; Ferris, Frederick L. ; Elman, Michael J. ; Antoszyk, Andrew ; Ruby, Alan ; Orth, David ; Bressler, Susan B. ; Fish, Gary ; Hubbard, Baker ; Klein, Michael ; Chandra, Suresh ; Blodi, Barbara ; Domalpally, Amitha ; Friberg, Thomas ; Wong, Wai ; Rosenfeld, Philip ; Agron, Elvira ; Toth, Cynthia ; Bernstein, Paul ; Sperduto, Robert</creator><creatorcontrib>Chew, Emily Y. ; Clemons, Traci E. ; SanGiovanni, John Paul ; Danis, Ronald P ; Ferris, Frederick L. ; Elman, Michael J. ; Antoszyk, Andrew ; Ruby, Alan ; Orth, David ; Bressler, Susan B. ; Fish, Gary ; Hubbard, Baker ; Klein, Michael ; Chandra, Suresh ; Blodi, Barbara ; Domalpally, Amitha ; Friberg, Thomas ; Wong, Wai ; Rosenfeld, Philip ; Agron, Elvira ; Toth, Cynthia ; Bernstein, Paul ; Sperduto, Robert</creatorcontrib><description>The Age-Related Eye Disease Study (AREDS) formulation for treatment of age-related macular degeneration contains vitamins C, E, beta-carotene and zinc with copper. Age-Related Eye Disease Study 2 (AREDS2) assessed the value of substituting lutein/zeaxanthin in the AREDS formulation because of the demonstrated risk of lung cancer from beta-carotene in smokers and former smokers. As previously reported in a secondary analysis, AREDS2 participants taking lutein/zeaxanthin with or without omega-3 long-chain polyunsaturated fatty 3 acids had a slightly lower progression rate to late AMD than participants not taking lutein/zeaxanthin.</description><identifier>ISSN: 2168-6165</identifier><identifier>EISSN: 2168-6173</identifier><identifier>DOI: 10.1001/jamaophthalmol.2013.7376</identifier><identifier>PMID: 24310343</identifier><language>eng</language><ispartof>JAMA ophthalmology, 2014-02, Vol.132 (2), p.142-149</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,782,786,887,27933,27934</link.rule.ids></links><search><creatorcontrib>Chew, Emily Y.</creatorcontrib><creatorcontrib>Clemons, Traci E.</creatorcontrib><creatorcontrib>SanGiovanni, John Paul</creatorcontrib><creatorcontrib>Danis, Ronald P</creatorcontrib><creatorcontrib>Ferris, Frederick L.</creatorcontrib><creatorcontrib>Elman, Michael J.</creatorcontrib><creatorcontrib>Antoszyk, Andrew</creatorcontrib><creatorcontrib>Ruby, Alan</creatorcontrib><creatorcontrib>Orth, David</creatorcontrib><creatorcontrib>Bressler, Susan B.</creatorcontrib><creatorcontrib>Fish, Gary</creatorcontrib><creatorcontrib>Hubbard, Baker</creatorcontrib><creatorcontrib>Klein, Michael</creatorcontrib><creatorcontrib>Chandra, Suresh</creatorcontrib><creatorcontrib>Blodi, Barbara</creatorcontrib><creatorcontrib>Domalpally, Amitha</creatorcontrib><creatorcontrib>Friberg, Thomas</creatorcontrib><creatorcontrib>Wong, Wai</creatorcontrib><creatorcontrib>Rosenfeld, Philip</creatorcontrib><creatorcontrib>Agron, Elvira</creatorcontrib><creatorcontrib>Toth, Cynthia</creatorcontrib><creatorcontrib>Bernstein, Paul</creatorcontrib><creatorcontrib>Sperduto, Robert</creatorcontrib><title>Secondary Analyses of the Effects of Lutein/Zeaxanthin on Age-Related Macular Degeneration Progression AREDS2 Report No.3</title><title>JAMA ophthalmology</title><description>The Age-Related Eye Disease Study (AREDS) formulation for treatment of age-related macular degeneration contains vitamins C, E, beta-carotene and zinc with copper. Age-Related Eye Disease Study 2 (AREDS2) assessed the value of substituting lutein/zeaxanthin in the AREDS formulation because of the demonstrated risk of lung cancer from beta-carotene in smokers and former smokers. As previously reported in a secondary analysis, AREDS2 participants taking lutein/zeaxanthin with or without omega-3 long-chain polyunsaturated fatty 3 acids had a slightly lower progression rate to late AMD than participants not taking lutein/zeaxanthin.</description><issn>2168-6165</issn><issn>2168-6173</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqlTsFKxDAUDKK4i-4_5AfaTZpu2pNQ3IoHFel68lKe7WubJU1Kkor791YRwbNzmRlmGIYQylnMGePbI4xgpyEMoEer44RxEWcik2dknXCZR5Jn4vxXy92KbLw_sgU5Y6nYXZJVkgrORCrW5HTAxpoW3IkWBvTJo6e2o2FAWnYdNuHbPswBldm-InyACYMy1Bpa9BhVqCFgSx-hmTU4usceDToIaik8O9s79P5LF1W5PyS0wsm6QJ9sLK7JRQfa4-aHr8jNXflyex9N89uIbYMmOND15NS4vKstqPpvYtRQ9_a9TqWQLE_Evwc-AV4GcMo</recordid><startdate>20140201</startdate><enddate>20140201</enddate><creator>Chew, Emily Y.</creator><creator>Clemons, Traci E.</creator><creator>SanGiovanni, John Paul</creator><creator>Danis, Ronald P</creator><creator>Ferris, Frederick L.</creator><creator>Elman, Michael J.</creator><creator>Antoszyk, Andrew</creator><creator>Ruby, Alan</creator><creator>Orth, David</creator><creator>Bressler, Susan B.</creator><creator>Fish, Gary</creator><creator>Hubbard, Baker</creator><creator>Klein, Michael</creator><creator>Chandra, Suresh</creator><creator>Blodi, Barbara</creator><creator>Domalpally, Amitha</creator><creator>Friberg, Thomas</creator><creator>Wong, Wai</creator><creator>Rosenfeld, Philip</creator><creator>Agron, Elvira</creator><creator>Toth, Cynthia</creator><creator>Bernstein, Paul</creator><creator>Sperduto, Robert</creator><scope>5PM</scope></search><sort><creationdate>20140201</creationdate><title>Secondary Analyses of the Effects of Lutein/Zeaxanthin on Age-Related Macular Degeneration Progression AREDS2 Report No.3</title><author>Chew, Emily Y. ; Clemons, Traci E. ; SanGiovanni, John Paul ; Danis, Ronald P ; Ferris, Frederick L. ; Elman, Michael J. ; Antoszyk, Andrew ; Ruby, Alan ; Orth, David ; Bressler, Susan B. ; Fish, Gary ; Hubbard, Baker ; Klein, Michael ; Chandra, Suresh ; Blodi, Barbara ; Domalpally, Amitha ; Friberg, Thomas ; Wong, Wai ; Rosenfeld, Philip ; Agron, Elvira ; Toth, Cynthia ; Bernstein, Paul ; Sperduto, Robert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_46360823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chew, Emily Y.</creatorcontrib><creatorcontrib>Clemons, Traci E.</creatorcontrib><creatorcontrib>SanGiovanni, John Paul</creatorcontrib><creatorcontrib>Danis, Ronald P</creatorcontrib><creatorcontrib>Ferris, Frederick L.</creatorcontrib><creatorcontrib>Elman, Michael J.</creatorcontrib><creatorcontrib>Antoszyk, Andrew</creatorcontrib><creatorcontrib>Ruby, Alan</creatorcontrib><creatorcontrib>Orth, David</creatorcontrib><creatorcontrib>Bressler, Susan B.</creatorcontrib><creatorcontrib>Fish, Gary</creatorcontrib><creatorcontrib>Hubbard, Baker</creatorcontrib><creatorcontrib>Klein, Michael</creatorcontrib><creatorcontrib>Chandra, Suresh</creatorcontrib><creatorcontrib>Blodi, Barbara</creatorcontrib><creatorcontrib>Domalpally, Amitha</creatorcontrib><creatorcontrib>Friberg, Thomas</creatorcontrib><creatorcontrib>Wong, Wai</creatorcontrib><creatorcontrib>Rosenfeld, Philip</creatorcontrib><creatorcontrib>Agron, Elvira</creatorcontrib><creatorcontrib>Toth, Cynthia</creatorcontrib><creatorcontrib>Bernstein, Paul</creatorcontrib><creatorcontrib>Sperduto, Robert</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><jtitle>JAMA ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chew, Emily Y.</au><au>Clemons, Traci E.</au><au>SanGiovanni, John Paul</au><au>Danis, Ronald P</au><au>Ferris, Frederick L.</au><au>Elman, Michael J.</au><au>Antoszyk, Andrew</au><au>Ruby, Alan</au><au>Orth, David</au><au>Bressler, Susan B.</au><au>Fish, Gary</au><au>Hubbard, Baker</au><au>Klein, Michael</au><au>Chandra, Suresh</au><au>Blodi, Barbara</au><au>Domalpally, Amitha</au><au>Friberg, Thomas</au><au>Wong, Wai</au><au>Rosenfeld, Philip</au><au>Agron, Elvira</au><au>Toth, Cynthia</au><au>Bernstein, Paul</au><au>Sperduto, Robert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Secondary Analyses of the Effects of Lutein/Zeaxanthin on Age-Related Macular Degeneration Progression AREDS2 Report No.3</atitle><jtitle>JAMA ophthalmology</jtitle><date>2014-02-01</date><risdate>2014</risdate><volume>132</volume><issue>2</issue><spage>142</spage><epage>149</epage><pages>142-149</pages><issn>2168-6165</issn><eissn>2168-6173</eissn><abstract>The Age-Related Eye Disease Study (AREDS) formulation for treatment of age-related macular degeneration contains vitamins C, E, beta-carotene and zinc with copper. Age-Related Eye Disease Study 2 (AREDS2) assessed the value of substituting lutein/zeaxanthin in the AREDS formulation because of the demonstrated risk of lung cancer from beta-carotene in smokers and former smokers. As previously reported in a secondary analysis, AREDS2 participants taking lutein/zeaxanthin with or without omega-3 long-chain polyunsaturated fatty 3 acids had a slightly lower progression rate to late AMD than participants not taking lutein/zeaxanthin.</abstract><pmid>24310343</pmid><doi>10.1001/jamaophthalmol.2013.7376</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2168-6165 |
| ispartof | JAMA ophthalmology, 2014-02, Vol.132 (2), p.142-149 |
| issn | 2168-6165 2168-6173 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4636082 |
| source | American Medical Association Journals |
| title | Secondary Analyses of the Effects of Lutein/Zeaxanthin on Age-Related Macular Degeneration Progression AREDS2 Report No.3 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T12%3A50%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Secondary%20Analyses%20of%20the%20Effects%20of%20Lutein/Zeaxanthin%20on%20Age-Related%20Macular%20Degeneration%20Progression%20AREDS2%20Report%20No.3&rft.jtitle=JAMA%20ophthalmology&rft.au=Chew,%20Emily%20Y.&rft.date=2014-02-01&rft.volume=132&rft.issue=2&rft.spage=142&rft.epage=149&rft.pages=142-149&rft.issn=2168-6165&rft.eissn=2168-6173&rft_id=info:doi/10.1001/jamaophthalmol.2013.7376&rft_dat=%3Cpubmedcentral%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_4636082%3C/pubmedcentral%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/24310343&rfr_iscdi=true |